Criterion and Construct Validity of the Beck Depression Inventory (BDI-II) to Measure Depression in Patients with Cancer: The Contribution of Somatic Items

Overview

Journal Int J Clin Health Psychol

Specialty Psychology

Date 2022 Dec 5

PMID 36467263

Authors

Silvia Almeida

Marta Camacho

J Bernardo Barahona-Correa

Jose Oliveira

Raquel Lemos

Daniel Rodrigues da Silva

Joaquim Alves da Silva

Telmo Mourinho Baptista

Jaime Gracio

Albino J Oliveira-Maia

Affiliations

Soon will be listed here.

Abstract

Background/objective: Screening for depression in patients with cancer can be difficult due to overlap between symptoms of depression and cancer. We assessed validity of the Beck Depression Inventory (BDI-II) in this population.

Method: Data was obtained in an outpatient neuropsychiatry unit treating patients with and without cancer. Psychometric properties of the BDI-II Portuguese version were assessed separately in 202 patients with cancer, and 376 outpatients with mental health complaints but without cancer.

Results: Confirmatory factor analysis suggested a three-factor structure model (cognitive, affective and somatic) provided best fit to data in both samples. Criterion validity was good for detecting depression in oncological patients, with an area under the ROC curve (AUC) of 0.85 (95% confidence interval [CI], 0.76-0.91). A cut-off score of 14 had sensitivity of 87% and specificity of 73%. Excluding somatic items did not significantly change the ROC curve for BDI-II (difference AUCs = 0.002, =0.9). A good criterion validity for BDI-II was also obtained in the non-oncological population (AUC = 0.87; 95% CI 0.81-0.91), with a cut-off of 18 (sensitivity=84%; specificity=73%).

Conclusions: The BDI-II demonstrated good psychometric properties in patients with cancer, comparable to a population without cancer. Exclusion of somatic items did not affect screening accuracy.

Citing Articles

The Chronic Headache Self-Efficacy Scale: Development and assessment of measurement properties.

Ginoza L, Sigman E, Michener L, Straub R, Sahai-Srivastava S, Pozzi F Headache. 2024; 65(3):460-472.

PMID: 39731352 PMC: 11884225. DOI: 10.1111/head.14888.

Elevated neopterin and decreased IL-4, BDNF levels and depression in lymphoma patients receiving R-CHOP chemotherapy.

Mishra P, Bhurani D, Nidhi Front Neurol. 2024; 15:1392275.

PMID: 39355088 PMC: 11442289. DOI: 10.3389/fneur.2024.1392275.

Mental Disorders, Social Media Addiction, and Academic Performance in Romanian Undergraduate Nursing Students.

David L, Ismaiel A, Foucambert P, Leucuta D, Popa S, Fadgyas Stanculete M J Clin Med. 2024; 13(15).

PMID: 39124742 PMC: 11312718. DOI: 10.3390/jcm13154475.

Research progress on the psychological burden and intervention measures in cancer patients.

Wang H, Lin H, Liu B Front Psychiatry. 2024; 15:1408762.

PMID: 38938456 PMC: 11208330. DOI: 10.3389/fpsyt.2024.1408762.

Physical activity and depression of Chinese college students: chain mediating role of rumination and anxiety.

Liu Y, Feng Q, Guo K Front Psychol. 2023; 14:1190836.

PMID: 37583607 PMC: 10423818. DOI: 10.3389/fpsyg.2023.1190836.

References

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

Bentler P . Comparative fit indexes in structural models. Psychol Bull. 1990; 107(2):238-46. DOI: 10.1037/0033-2909.107.2.238. View

Kojima M, Furukawa T, Takahashi H, Kawai M, Nagaya T, Tokudome S . Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Res. 2002; 110(3):291-9. DOI: 10.1016/s0165-1781(02)00106-3. View

Wakefield C, Butow P, Aaronson N, Hack T, Hulbert-Williams N, Jacobsen P . Patient-reported depression measures in cancer: a meta-review. Lancet Psychiatry. 2015; 2(7):635-47. DOI: 10.1016/S2215-0366(15)00168-6. View

Vodermaier A, Linden W, Siu C . Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst. 2009; 101(21):1464-88. PMC: 3298956. DOI: 10.1093/jnci/djp336. View

Warmenhoven F, van Rijswijk E, Engels Y, Kan C, Prins J, van Weel C . The Beck Depression Inventory (BDI-II) and a single screening question as screening tools for depressive disorder in Dutch advanced cancer patients. Support Care Cancer. 2011; 20(2):319-24. PMC: 3244603. DOI: 10.1007/s00520-010-1082-8. View

Tobias K, Lehrfeld J, Rosenfeld B, Pessin H, Breitbart W . Confirmatory factor analysis of the Beck Depression Inventory-II in patients with advanced cancer: A theory-driven approach. Palliat Support Care. 2017; 15(6):704-709. PMC: 5716931. DOI: 10.1017/S1478951517000724. View

Kroenke K, Spitzer R, Williams J . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-13. PMC: 1495268. DOI: 10.1046/j.1525-1497.2001.016009606.x. View

Rice M, Harris G . Comparing effect sizes in follow-up studies: ROC Area, Cohen's d, and r. Law Hum Behav. 2005; 29(5):615-20. DOI: 10.1007/s10979-005-6832-7. View

10.

Nejati S, Ariai N, Bjorkelund C, Skoglund I, Petersson E, Augustsson P . Correspondence Between the Neuropsychiatric Interview M.I.N.I. and the BDI-II and MADRS-S Self-Rating Instruments as Diagnostic Tools in Primary Care Patients with Depression. Int J Gen Med. 2020; 13:177-183. PMC: 7234955. DOI: 10.2147/IJGM.S243150. View

11.

Wang Y, Gorenstein C . Assessment of depression in medical patients: a systematic review of the utility of the Beck Depression Inventory-II. Clinics (Sao Paulo). 2013; 68(9):1274-87. PMC: 3782729. DOI: 10.6061/clinics/2013(09)15. View

12.

Chida Y, Hamer M, Wardle J, Steptoe A . Do stress-related psychosocial factors contribute to cancer incidence and survival?. Nat Clin Pract Oncol. 2008; 5(8):466-75. DOI: 10.1038/ncponc1134. View

13.

Brouwer D, Meijer R, Zevalkink J . On the factor structure of the Beck Depression Inventory-II: G is the key. Psychol Assess. 2012; 25(1):136-45. DOI: 10.1037/a0029228. View

14.

Katz M, Kopek N, Waldron J, Devins G, Tomlinson G . Screening for depression in head and neck cancer. Psychooncology. 2004; 13(4):269-80. DOI: 10.1002/pon.734. View

15.

Walker J, Holm Hansen C, Martin P, Symeonides S, Ramessur R, Murray G . Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry. 2015; 1(5):343-50. DOI: 10.1016/S2215-0366(14)70313-X. View

16.

Massie M . Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004; (32):57-71. DOI: 10.1093/jncimonographs/lgh014. View

17.

Mitchell A, Meader N, Davies E, Clover K, Carter G, Loscalzo M . Meta-analysis of screening and case finding tools for depression in cancer: evidence based recommendations for clinical practice on behalf of the Depression in Cancer Care consensus group. J Affect Disord. 2012; 140(2):149-60. DOI: 10.1016/j.jad.2011.12.043. View

18.

Mallinckrodt C, Prakash A, Houston J, Swindle R, Detke M, Fava M . Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology. 2007; 56(2-3):73-85. DOI: 10.1159/000111537. View

19.

Hopko D, Bell J, Armento M, Robertson S, Hunt M, Wolf N . The phenomenology and screening of clinical depression in cancer patients. J Psychosoc Oncol. 2007; 26(1):31-51. DOI: 10.1300/j077v26n01_03. View

20.

Arnau R, Meagher M, Norris M, Bramson R . Psychometric evaluation of the Beck Depression Inventory-II with primary care medical patients. Health Psychol. 2001; 20(2):112-9. DOI: 10.1037//0278-6133.20.2.112. View